Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Frontiers in Digital Health
|
June 15, 2026
Text-guided few-shot liver and tumor segmentation
Hongling Chen, Aibing Xu, Li Zhang, et al.
Biomed Research International
|
August 28, 2020
Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta-Analysis
Siyuan Tian, Yang Yu, Honghua Huang, et al.
Clinical Medicine Insights. Oncology
|
June 28, 2023
Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
Dongxu Zhao, Wei Xu, Yi Zhan, et al.
Cancer Science
|
May 8, 2020
Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression
Yang Yu, Qiaoyu Chen, Xunlei Zhang, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
July 26, 2012
The alternative crosstalk between RAGE and nitrative thioredoxin inactivation during diabetic myocardial ischemia-reperfusion injury
Yi Liu, Yan Qu, Rutao Wang, et al.
Frontiers in Immunology
|
November 9, 2023
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial
Qian Qiao, Chun Han, Sisi Ye, et al.
Liver Cancer
|
August 8, 2024
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Shukui Qin, Weijia Fang, Zhenggang Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2025
Porustobart (HBM4003) plus toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I study
Ningning Zhang, Tian Liu, Ming Luo, et al.
The Lancet. Oncology
|
May 11, 2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
Jian Zhou, Li Bai, Jia Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Frontiers in Digital Health
|
June 15, 2026
Text-guided few-shot liver and tumor segmentation
Hongling Chen, Aibing Xu, Li Zhang, et al.
Biomed Research International
|
August 28, 2020
Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta-Analysis
Siyuan Tian, Yang Yu, Honghua Huang, et al.
Clinical Medicine Insights. Oncology
|
June 28, 2023
Development and Validation of Nomograms to Predict the Prognosis of Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
Dongxu Zhao, Wei Xu, Yi Zhan, et al.
Cancer Science
|
May 8, 2020
Long noncoding RNA ANRIL promotes the malignant progression of cholangiocarcinoma by epigenetically repressing ERRFI1 expression
Yang Yu, Qiaoyu Chen, Xunlei Zhang, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
July 26, 2012
The alternative crosstalk between RAGE and nitrative thioredoxin inactivation during diabetic myocardial ischemia-reperfusion injury
Yi Liu, Yan Qu, Rutao Wang, et al.
Frontiers in Immunology
|
November 9, 2023
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial
Qian Qiao, Chun Han, Sisi Ye, et al.
Liver Cancer
|
August 8, 2024
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Shukui Qin, Weijia Fang, Zhenggang Ren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2025
Porustobart (HBM4003) plus toripalimab as second-line therapy in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase I study
Ningning Zhang, Tian Liu, Ming Luo, et al.
The Lancet. Oncology
|
May 11, 2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
Jian Zhou, Li Bai, Jia Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2021
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
Shukui Qin, Feng Bi, Shanzhi Gu, et al.
Page
of 2